PepGen Inc (PEPG)
14.56
+0.32
(+2.25%)
USD |
NASDAQ |
May 24, 16:00
14.60
+0.04
(+0.27%)
After-Hours: 20:00
PepGen Cash from Financing (TTM): 86.65M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 86.65M |
| December 31, 2023 | -0.189M |
| September 30, 2023 | 0.002M |
| June 30, 2023 | -0.884M |
| March 31, 2023 | 112.34M |
| Date | Value |
|---|---|
| December 31, 2022 | 112.19M |
| September 30, 2022 | 110.95M |
| June 30, 2022 | 245.24M |
| March 31, 2022 | 147.64M |
| December 31, 2021 | 147.66M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.884M
Minimum
Jun 2023
245.24M
Maximum
Jun 2022
96.16M
Average
111.57M
Median
Cash from Financing (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 130.04M |
| Vertex Pharmaceuticals Inc | -625.00M |
| Sarepta Therapeutics Inc | 45.35M |
| PTC Therapeutics Inc | 642.85M |
| Regenxbio Inc | 94.80M |